Background/Aims: To investigate the role of methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) in the clinical prognosis and cell biology of renal cell carcinoma (RCC). Methods: A total of 137 RCC tissues were evaluated by immunohistochemistry. The relationship between MTHFD2 overexpression and clinical parameters and vimentin expression was assessed. Kaplan-Meier curves and the log-rank test were applied for survival analysis according to MTHFD2 and vimentin expression in RCC tissues. The expression of MTHFD2 mRNA and protein was examined by quantitative reverse transcription PCR and western blotting, respectively. To determine further the biological activity of MTHFD2 in RCC, 786-O cells were transfected with short hairpin RNA specifically targeting MTHFD2 (shMTHFD2) with or without tumor necrosis factor (TNF)-α stimulation. Cell proliferation, cell migration and invasion and drug sensitivity were subsequently assessed using Cell Counting Kit-8, wound healing, and Transwell assays. Results: Immunohistochemical analysis demonstrated that both MTHFD2 and vimentin overexpression was positively associated with clinical staging, pathological grade, and poor overall survival (all P < 0.05). MTHFD2 expression was closely correlated with vimentin overexpression in RCC (r = 0.402, P < 0.001). After knocking down MTHFD2 expression in 786-O cells, decreased cell proliferation, migration, and invasion were observed and accompanied by the reduced expression of vimentin. The effects of MTHFD2 down-regulation could be partially restrained by TNF-α treatment. Vimentin expression and cell migration and invasion,
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Introduction
Renal cell carcinoma (RCC) is the ninth most common cancer worldwide. Neoplasms of the kidney (including the renal pelvis) are estimated to occur in 65, 340 patients in the United States and result in 14, 970 deaths in 2018 [1] . Approximately 17% of patients who present with metastatic disease are diagnosed with de novo RCC in the United States [2] . Therapy for RCC has changed greatly over the last decade, especially for those patients with advanced disease. Therapies targeting tumor vasculature are now the mainstays for the treatment of metastatic RCC. However, most patients ultimately die due to the gradual development of resistance in the tumor to antiangiogenic therapy. Therefore, new therapeutic approaches for patients with advanced RCC are urgently needed.
Divergent metabolic remodeling is regarded as a hallmark of malignant tumors. Recently, studies have shown that metabolic enzymes may act as oncogenes [3] and can even transform cells [4] . Nilsson et al. found that methylenetetrahydrofolate dehydrogenase 2 (MTHFD2), which has a role in mitochondrial folate metabolism, is markedly elevated in many cancers, including RCC, and positively correlated with poor prognosis in patients with breast cancer [5] . Moreover, MTHFD2 expression is very low in most healthy adult tissues, even those that actively proliferate [5, 6] . These features make it an ideal diagnostic marker for cancer and even a treatment target. However, the role of MTHFD2 in RCC has not been examined.
Normally, the enzymes involved in folate metabolism are targets of chemotherapy drugs such as methotrexate and 5-fluorouracil (5-FU); however, RCC has been demonstrated to be refractory to chemotherapy. Quite recently, researchers have shown that MTHFD2 may have an impact on cell proliferation independent of its enzymatic activity [7] , which may suggest that inhibiting its enzymatic activity alone may not be sufficient to stop tumor progression. Although the enzymatic activity of MTHFD2 has been well characterized, little is known about its role in RCC cell biology. Lehtinen et al. demonstrated that MTHFD2 is a novel regulator of vimentin expression by high-throughput RNA interference (RNAi) screening [8] . It has been proposed that MTHFD2 might be a novel factor in cell proliferation [9] and has been proven to be essential for tumor metastasis [10] .
In this study, we found that MTHFD2 overexpression in RCC tissues was positively associated with tumor grade, tumor-node-metastasis (TNM) stage, vimentin expression, and poor survival. By knocking down MTHFD2 expression in RCC cell lines, we found that cell proliferation was significantly decreased. Additionally, we demonstrated that MTHFD2 deletion can reduce cell migration and invasion, which was possibly modulated by the reduced expression of vimentin. Furthermore, we showed that MTHFD2 down-regulation may increase the sensitivity of RCC cells to chemotherapy. These findings indicate that MTHFD2 overexpression plays a pivotal role in the progression of RCC and might be a potential target for RCC therapy.
Materials and Methods

Patients and tissue samples
This study was approved by the Medical Ethics Committee of Sun Yat-sen University, and written informed consent was obtained from each patient for surgery and research purposes. A total of 137 patients with RCC from the First Affiliated Hospital of Sun Yat-sen University were enrolled in this study [11] and graded according to the criteria of the World Health Organization [12, 13] .
Cell lines
The RCC cell lines 786-O, ACHN, and 769-P were obtained from the American Type Culture Collection (Manassas, VA) and cultured in RPMI-1640 (Gibco, Gaithersburg, MD) supplemented with 10% fetal bovine serum (FBS; Gibco). OS-RC-2 cells were a kind gift from Dr. Shenjie Guo (Department of Urology, Sun Yat-sen University Cancer Center) and were also maintained in RPMI-1640 (Gibco) supplemented with 10% FBS (Gibco). All cells were kept in a 37°C humidified incubator with 95% O 2 and 5% CO 2 .
Immunohistochemistry
Immunohistochemical (IHC) staining was performed as described previously [5] . Polyclonal rabbit IgG anti-MTHFD2 (1:200; Abcam, Cambridge, MA) and polyclonal rabbit IgG anti-vimentin (1:200; Cell Signaling Technology, Danvers, MA) antibodies were used for IHC. All sections were assessed and scored by two independent pathologists based on staining intensity and the percentage of positive tumor cells, as described previously [5] . Staining intensity was graded as: negative = 0; weak = 1; moderate = 2; and strong = 3. The percentage of positive-staining cells was scored as: <5% = 0; 6-25% = 1; 26-50% = 2; 51-75% = 3; and >76% = 4. The total score was obtained by multiplying intensity by proportion (intensity score × proportion score). Positive staining was defined as a staining index ≥4, whereas negative staining was defined as a staining index <4.
RNA extraction and quantitative reverse transcription polymerase chain reaction
Total cellular RNA was isolated using the PureLink ® R RNA Mini Kit (Ambion, Foster City, CA), reverse transcribed to cDNA using a RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific, Waltham, MA), and analyzed by quantitative reverse transcription PCR (TaKaRa Biotechnology Co., Ltd., Shiga, Japan) according to the manufacturers' instructions. The primer sequences are listed in Table 1 .
Western blot analysis
Whole cell lysates were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto polyvinylidene difluoride membranes. The membranes were blocked and incubated with antibodies targeting MTHFD2 (1:1000; Abcam) or vimentin (1:1000; Cell Signaling Technology). A horseradish peroxidase-conjugated goat anti-rabbit secondary antibody (1:5000; Abcam) was used to detect the specific bands.
Cell proliferation assay
Cell proliferation was tested using a Cell Counting Kit-8 (CCK-8; Dojindo Laboratories, Kumamoto, Japan). The cells were seeded in 96-well plates at 4000 cells/100 μL/well and transfected with short hairpin RNA (shRNA) targeting MTHFD2 (shMTHFD2) or negative control shRNA, followed by incubation at 37°C in an environment with 5% CO 2 for 48 h. After transfection, the cells were treated with or without human recombinant tumor necrosis factor (TNF)-α (50 ng/mL; Invitrogen) and cultured for an additional 48 h. Then, 10 μL CCK-8 solution was added to each well, followed by incubation for 2 h. Optical density was measured at 450 nm with a microplate reader at 4d, 5d, 6d, and 7dafter transfection. All experiments were carried out in triplicate. Cell transfection and tumor necrosis factor-α stimulation 786-O cells were transfected with shMTHFD2 (sc-75937-SH; Santa Cruz Biotechnology, Inc., Dallas, TX) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) and Opti-MEM I (Gibco). At 6 h after transfection, shRNA was removed by changing the medium with RPMI-1640 with 10% FBS, and the cells were cultured for an additional 48-72 h. After transfection, the cells were treated with or without TNF-α (50 ng/mL; Invitrogen) and cultured for an additional 48 h, and then total RNA or protein was harvested for analysis.
Wound healing and invasion assays
For the wound healing assay, the cells were plated in 6-well culture plates. When the cells grew to confluence, a straight scratch was made in the center of each well using a micropipette tip, and the cells were washed with phosphate-buffered saline (PBS) and incubated in serum-free medium. The initial gap length and residual gap length at 0, 12, and 24 h after wounding were observed under an inverted microscope and photographed. Wound area was measured using ImageJ software (http://rsb.info.nih.gov/ij/). The percentage of wound closure was estimated by 1 − (wound area at Tt)/(wound area at T0) × 100, where Tt is the time after wounding and T0 is the time immediately after wounding.
For the invasion assay, 500 μL of a serum-free suspension of cells (1.0 × 10 5 cells/mL) was added to the interior of each Transwell insert (pore size, 8 μm); 500 μL medium containing 10% FBS was added to the lower chamber of the insert. The cells were incubated at 37°C in a 5% CO 2 atmosphere for 36-48 h. Then, the non-invading cells in the interior of the insert were removed gently with a cotton-tipped swab; the invasive cells on the lower surface of the inserts were stained with the staining solution for 20 min and counted under a microscope. Each experiment was performed in triplicate.
Drug sensitivity assay
Cells transfected with shMTHFD2#1/2 or the negative control plasmid were plated in 96-well plates (500 cells/well) and cultured with the topoisomerase II inhibitor antineoplastic agent mitoxantrone (MTX; Sigma-Aldrich, St. Louis, MO) or 5-FU (Sigma-Aldrich) diluted in PBS at different concentrations. Four parallel wells were set for each group. After incubation for 24 h with MTX or 5-FU, the absorbance of each well at a wavelength of 450 nm (A450) was measured. The cell survival rate (%) was calculated using the formula: (mean A450 of the test wells)/(mean A450 of the control wells) × 100. The inhibition rate (%) was calculated using the formula: 100 − survival rate.
Statistical analysis
Data were evaluated using SPSS 13.0 (SPSS, Inc., Chicago, IL) and GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA). All experiments were repeated at least three times. Continuous data are expressed as the mean ± standard deviation and analyzed by the t-test or one-way analysis of variance followed by Bonferroni's post-hoc test. The relationship between MTHFD2 and vimentin expression and clinical features were assessed by the chi-square test. The correlation between MTHFD2 and vimentin expression was assessed by Spearman's test. Disease-specific survival was analyzed by the Kaplan-Meier method. Differences in survival were tested by the log-rank test. Statistical significance was established at P < 0.05.
Results
MTHFD2 is highly expressed in RCC tissues and is positively associated with grade, stage, and vimentin overexpression
To evaluate whether MTHFD2 was overexpressed in RCC tissues, we performed IHC in 137 RCC tissues. Positive MTHFD2 staining was observed in 80 of the 137 RCC tissues (58.39%, Fig. 1A, B) . Furthermore, MTHFD2 was significantly associated with tumor stage and pathological grade (both P < 0.01). Interestingly, MTHFD2 staining was positively associated with clear cell RCC (P = 0.004, Table 1 ).
Of the 137 specimens, 97 were positive for vimentin expression (70.8%, Fig. 1C, D) . Vimentin was also significantly associated with TNM stage and pathological grade (both P < 0.01). Similar to the expression pattern of MTHFD2, vimentin was predominantly expressed
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Be a Novel Target For Cancer Therapy in clear cell RCC (P < 0.001), but not in chromophobe or papillary RCC (Table 2) . However, neither MTHFD2 nor vimentin was positively associated with sex, age, or location (all P > 0.05, Table 2 ). In the 137 tissues, positive vimentin expression was detected in 69 of the 80 tissues in the MTHFD2-positive group and 28 of the 57 tissues in the MTHFD2-negative group. Furthermore, correlation analysis demonstrated that MTHFD2 overexpression was significantly correlated with vimentin overexpression (r = 0.402, P < 0.001).
MTHFD2 and vimentin overexpression predicts poor prognosis in RCC
Survival analysis confirmed that patients with MTHFD2-positive expression had a shorter OS time compared to those with MTHFD2-negative expression (P = 0.036). The medium OS time was 56.467 months (95% confidence interval [CI] 54.535-58.398) for the MTHFD2- Fig. 1C, F) .
MTHFD2 is highly expressed in 786-O, ACHN, and OS-RC-2 cells compared to 769-P cells at both the mRNA and protein level
To explore further the role of MTHFD2 in RCC cell biology, we used cell lines for our subsequent in vitro study. We found that the 786-O, ACHN, and OS-RC-2 cell lines expressed higher levels of MTHFD2 than the 769-P cell line at both the mRNA and protein level (Fig. 2) .
MTHFD2 knockdown in 786-O cells decreases cell proliferation, migration, and invasion by reducing vimentin expression
To determine the role of MTHFD2 in cell biology, we down-regulated the expression of MTHFD2 in 786-O cells. As shown in Fig. 3 , MTHFD2 mRNA was significantly decreased in 786-O cells after transfection with shMTHFD2. A CCK-8 assay was carried out to test the effects of decreased MTHFD2 expression on the proliferation of 786-O cells. The results showed that the growth of cells with lower MTHFD2 expression was significantly affected in comparison with those in the control group (Fig. 3C , P < 0.05). Migration and invasion were tested by a wound healing experiment and a Transwell assay. Wound closure was significantly impaired in cells with MTHFD2 down-regulation (Fig. 3D , E, P < 0.05). Similarly, knocking down MTHFD2 expression led to a significant decrease in cell invasion through the Matrigel matrix (Fig. 3D, F , P < 0.05). Furthermore, we found that vimentin expression was reduced by MTHFD2 depletion (Fig.  3B , P < 0.05). To investigate whether the reduction of migration and invasion was modulated by vimentin, cells infected with shMTHFD2 were treated with TNF-α, which enhances the expression of vimentin in RCC cells [14] . We found that TNF-α could reverse the downregulation of vimentin following MTHFD2 knockdown (Fig. 3B) . In addition, treatment with TNF-α inhibited MTHFD2-mediated cellular migration and invasion (Fig. 3D , E, F, P > 0.05). However, the reduced cell proliferation rate caused by MTHFD2 depletion was not affected by TNF-α stimulation (Fig. 3C , P < 0.05).
MTHFD2 down-regulation sensitizes 786-O cells to chemotherapy drugs
To test whether MTHFD2 sensitizes RCC cells to chemotherapy drugs, shRNA-transfected 786-O and control cells were treated with different concentrations of MTX and 5-FU. The cells transfected with shMTHFD2 showed a lower survival rate than those in the control group after treatment with MTX or 5-FU (Fig. 4 , P < 0.05). [15] . Recently, MTHFD2 has been demonstrated to be overexpressed in rapidly growing malignant tumors and to participate in the mitochondrial folate pathway to produce additional purines due to increased growth demand [16] . Nilsson et al. identified MTHFD2 as one of the most consistently overexpressed mRNAs across 19 different tumors; moreover, they found that MTHFD2 protein was present in a variety of different cancers, including RCC [5] . In the present study, we also demonstrated that MTHFD2 was overexpressed in RCC tissues. Furthermore, we confirmed that MTHFD2 overexpression was positively associated with pathological grade and tumor stage. These findings suggested that MTHFD2, which deserves further intensive study, may play an important role in the progression of RCC.
Recently, Lehtinen et al. identified MTHFD2 as a vimentin modulator through highthroughput RNAi screening in breast cancer cells [8] . Vimentin is a key regulator of epithelialmesenchymal transition [17] . In RCC, vimentin has been shown to be an independent predictor of tumor recurrence and OS in patients with clear cell RCC [18] . Despite its clinical significance, the relationship between MTHFD2 and vimentin in RCC has yet to be determined. According to our study, the expression of MTHFD2 was positively associated with vimentin expression in RCC tissues. Interestingly, while MTHFD2 can hardly be detected in papillary or chromophobe RCC, vimentin expression was also significantly associated with clear cell RCC in our experiments. Actually, vimentin has been proven to be a marker that can distinguish chromophobe RCC from clear cell RCC and renal oncocytoma [19, 20] . However, due to an insufficient number of samples of the other two types of RCC in our trial, we were unable to determine definitively the expression pattern of MTHFD2 in different pathological types of RCC. Further studies in larger cohorts of papillary and chromophobe RCC would be of great important.
Nilsson et al. found that MTHFD2 overexpression was positively associated with increased mortality in patients with breast cancer [5] . Similarly, we also observed that the OS of RCC patients with positive MTHFD2 expression was significantly shorter than that of patients with negative MTHFD2 expression. These findings may suggest a potential role for MTHFD2 in the progression of RCC. According to our research, RCC patients with high vimentin expression had a worse prognosis than those with low vimentin expression. This was consistent with the findings of other studies that also validated the role of vimentin in predicting the poor outcome of patients with RCC [18, 21] .
Independent of its dehydrogenase activity, MTHFD2 can drive cancer cell proliferation [7] . However, Lehtinen et al. found that inhibition of MTHFD2 did not significantly decrease cell proliferation or induce cell apoptosis in some breast cancer cells [8] . In the present study, we observed that MTHFD2 depletion significantly decreased the proliferation of RCC cells, which was in accordance with a study by Selcuklu et al. who identified MTHFD2 as a microRNA-9 target gene that affects the proliferation of breast cancer cells [22] . These findings may indicate a heterogenic property of MTHFD2 in cell biology. Moreover, we observed a reduction of the migration and invasion of 786-O cells following MTHFD2 knockdown, which was accompanied with the decreased expression of vimentin. These results were in agreement with those of Lehtinen et al. in breast cancer cells [8] . Since vimentin is a regulator of cell migration and invasion in RCC cells [23] , we hypothesized that MTHFD2 may affect cell migration and invasion through the reduction of vimentin expression.
We then performed a rescue assay by TNF-α stimulation. TNF-α increases cell migration and invasion through epithelial-mesenchymal transition via the NF-κB pathway [24, 25] . We demonstrated that TNF-α could restore vimentin expression, which subsequently blocked the inhibitory influence of MTHFD2 knockdown on cell migration and invasion, in accordance with the findings of Ho et al. [14] . However, Ho et al. confirmed that TNF-α could enhance the tumorigenicity of RCC cells. In the present study, the low cell viability induced by shMTHFD2 was not significantly counteracted by TNF-α treatment. Taken together, our results indicated [26] . Although moleculartargeted therapy can offer significant clinical benefits for metastatic RCC, its effectiveness eventually declines with the development of resistance [27] . Recently, it was found that MTHFD2 suppression may increase the sensitivity of breast cancer cells to folate depletion [28] . Our study is consistent with this report, as the loss of MTHFD2 increased the sensitivity of 786-O cells to chemotherapy drugs.
Conclusion
In summary, our study indicated that MTHFD2 is an important regulator of the progression of RCC and may be a marker for poor prognosis in the clinical setting. Downregulation of MTHFD2 suppressed cell proliferation and vimentin expression, which subsequently reduced cell migration and invasion. Therefore, targeting MTHFD2 may be a novel strategy for the treatment of RCC.
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